Alpha Feto Protein (AFP)-Ascitic Fluid, in Visit Clinic

The alpha‑fetoprotein (AFP) test measures AFP protein levels in blood. In pregnancy, maternal serum AFP screens for neural tube defects and helps assess risk of chromosomal abnormalities. In nonpregnant adults, AFP is used as a tumor marker—particularly for hepatocellular carcinoma and some germ cell tumors—to aid diagnosis, monitor treatment response, and detect recurrence. Results need clinical correlation and follow‑up testing.

An elevated alpha‑fetoprotein (AFP) can mean different things depending on context. In pregnancy it may indicate neural tube or abdominal wall defects, multiple pregnancy, or dating errors, requiring ultrasound and repeat testing. In non‑pregnant adults it’s a marker for liver disease (hepatitis, cirrhosis), hepatocellular carcinoma, or certain germ‑cell tumors. False positives occur, so further evaluation and specialist referral are needed.

A positive/elevated AFP means higher-than-normal alpha‑fetoprotein levels. In pregnancy it may indicate neural tube or abdominal wall defects, multiple pregnancy, wrong dating, or placental problems and requires further ultrasound and testing. In adults an elevated AFP can signal liver disease (including hepatocellular carcinoma) or germ‑cell tumors, and warrants imaging and specialist evaluation.

Alpha‑fetoprotein (AFP) is a blood protein normally made by the fetal liver. In adults, elevated AFP can signal hepatocellular carcinoma (HCC) or other tumors; chronic hepatitis and cirrhosis may cause mild increases. AFP is used alongside imaging for HCC surveillance—very high or rising levels (often >400 ng/mL) raise concern but are not diagnostic on their own.

Yes—fatty liver (NAFLD/NASH) can cause mild AFP elevations from inflammation, regeneration, or advanced fibrosis/cirrhosis. Markedly elevated AFP is more suggestive of hepatocellular carcinoma or germ‑cell tumors. Any unexplained or rising AFP warrants further evaluation, such as repeat testing, liver imaging (ultrasound or MRI), and hepatology referral to exclude malignancy.

Alpha-fetoprotein (AFP) is the primary blood marker for hepatocellular carcinoma (primary liver cancer). Elevated AFP supports diagnosis and is used for screening and monitoring treatment response, though sensitivity and specificity are limited. Additional markers include AFP‑L3 and des-gamma-carboxy prothrombin (DCP/PIVKA‑II); CEA or CA19‑9 may suggest metastatic liver lesions from other primaries.